SRC and melanoma: In the present study, we demonstrated that treatment of human metastatic and non-metastatic melanoma cells with 3, 3′- (3, 5-DCPBC) profoundly diminished phosphorylation of the Epidermal Growth Factor Receptor (EGFR), proto-oncogene cellular sarcoma (c-SRC) and simultaneously suppressed phosphorylation of key downstream effectors and signaling pathways known to enforce melanoma progression.